Sera Prognostics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Sera Prognostics, Inc. | SERA - NASDAQ |
$15.00-$17.00 | $16.00 | $15.01 | 4.7 million | 7/15/2021 |
| Citigroup, Cowen, William Blair | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-06-11 Terms Added 2021-07-08 | ||||||
Sera Prognostics, Inc. Quote & Chart - Click for current quote - SERA
IPO Boutique aggregates information on public companies and private companies, such as "SERA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Sera Prognostics, Inc. (adapted from Sera Prognostics, Inc. prospectus):
They are a women’s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a women’s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "SERA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.